Celldex Therapeutics (CLDX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Phase 3 CSU studies met primary and key secondary endpoints, supporting a planned 2027 BLA filing for barzolvolimab; treatment continues through Week 52.
Liquidity was $650.3M at September 30, with planned operations expected to be funded through 2028, subject to a potential milestone payment; 9M net loss widened as development and commercial-planning costs increased.
Financial highlights
Q3 R&D was $67.4M vs. $62.9M and G&A was $14.8M vs. $10.7M; 9M R&D was $208.0M vs. $169.7M and G&A was $39.4M vs. $31.9M.
Q3 operating expenses were $82.3M, up 12% YoY; 9M expenses rose 23% to $247.3M. Operating losses were $82.3M and $247.3M, respectively.
Net loss was $75.6M, or $0.96/share, in Q3 and $227.7M, or $3.06/share, for 9M; prior-year losses were $67.0M and $177.4M.
Q3 revenue was $0; 9M revenue was $37K vs. $1.424M, mainly reflecting lower Rockefeller University contract and services revenue.
Outlook and guidance
Planned FDA BLA submission for barzolvolimab in CSU in 2027; both Phase 3 CSU trials continue treatment through Week 52.
Phase 2 atopic dermatitis topline data expected in late 2026; ColdU and symptomatic dermographism Phase 3 studies are enrolling, with updates expected in 2027.
Cash used in operations is expected to increase over the next 12 months, primarily with barzolvolimab development; personnel, product development, facility and commercial-planning costs are also expected to rise.
Rockefeller services revenue may rise but fluctuate by quarter; additional barzolvolimab indications were planned for announcement by year end.
Latest events from Celldex Therapeutics
- Majority complete responses support a planned 2027 BLA and launch preparations.CLDX
3rd Annual Guggenheim Healthcare Innovation Conference - Barzolvolimab achieved rapid, durable efficacy and safety in severe, refractory CSU, meeting all endpoints.CLDX
Study result - Barzolvolimab's phase III data and commercial plans highlight innovation in advanced urticaria therapy.CLDX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Barzolvolimab delivers rapid, durable efficacy in CSU, with major data milestones expected in 2026.CLDX
Corporate presentation - Q2 2026 net loss rose 30% as R&D spending surged, but liquidity remains strong through 2028.CLDX
Q2 2026 - No efficacy seen in prurigo nodularis; program discontinued, safety profile remains favorable.CLDX
Study result - Phase 2 and 52-week data in CSU and CIndU drive phase 3 launches and broad clinical expansion.CLDX
Guggenheim Securities Inaugural Healthcare Innovation Conference - All proposals passed, with strong financials and pipeline progress highlighted.CLDX
AGM 2026 - Barzolvolimab showed rapid, significant disease control in CIndU and is advancing to Phase 3.CLDX
Status Update